- Previous Close
1.3250 - Open
1.3000 - Bid 1.3450 x --
- Ask 1.3750 x --
- Day's Range
1.2950 - 1.3800 - 52 Week Range
0.3500 - 1.6600 - Volume
1,066,356 - Avg. Volume
1,472,045 - Market Cap (intraday)
328.727M - Beta (5Y Monthly) 0.86
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0400 - Earnings Date Feb 21, 2025 - Feb 25, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia, the United States, the United Kingdom, and the European Union. The company offers Ortho-ATI, a cell therapy for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; Remplir, a collagen scaffold used in peripheral nerve repair; and Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
orthocell.comRecent News: OCC.AX
View MorePerformance Overview: OCC.AX
Trailing total returns as of 1/17/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OCC.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OCC.AX
View MoreValuation Measures
Market Cap
328.73M
Enterprise Value
308.80M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
52.07
Price/Book (mrq)
72.53
Enterprise Value/Revenue
58.10
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-135.10%
Return on Assets (ttm)
-25.04%
Return on Equity (ttm)
-134.46%
Revenue (ttm)
5.32M
Net Income Avi to Common (ttm)
-7.18M
Diluted EPS (ttm)
-0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
20.61M
Total Debt/Equity (mrq)
15.22%
Levered Free Cash Flow (ttm)
-4.91M